AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VOR
  4. [Form 4] Vor Biopharma Inc. Insider Trading Activity

[Form 4] Vor Biopharma Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Jean-Paul Kress, CEO, Chairman and Director of Vor Biopharma, was granted a significant stock option award on June 26, 2025. The derivative securities transaction involved 83,296,638 stock options with the following key terms:

  • Exercise price set at $0.89 per share
  • Options expire on June 25, 2035
  • Vesting schedule: 25% vests on June 26, 2026, with remaining 75% vesting in equal monthly installments over 3 years
  • Vesting contingent on continued service with company

This substantial equity grant aligns the CEO's interests with shareholders and suggests long-term commitment to the company. The low exercise price relative to typical biotech stock prices may indicate recent market challenges or strategic compensation planning.

Jean-Paul Kress, CEO, Presidente e Direttore di Vor Biopharma, ha ricevuto un importante premio in opzioni azionarie il 26 giugno 2025. La transazione riguardante strumenti derivati ha coinvolto 83.296.638 opzioni azionarie con le seguenti condizioni principali:

  • Prezzo di esercizio fissato a 0,89 $ per azione
  • Le opzioni scadono il 25 giugno 2035
  • Piano di maturazione: 25% matura il 26 giugno 2026, mentre il restante 75% matura in rate mensili uguali distribuite su 3 anni
  • La maturazione 猫 subordinata alla continuazione del servizio in azienda

Questa consistente assegnazione di azioni allinea gli interessi del CEO con quelli degli azionisti e indica un impegno a lungo termine verso l鈥檃zienda. Il prezzo di esercizio basso, rispetto ai tipici valori delle azioni biotech, potrebbe riflettere recenti difficolt脿 di mercato o una strategia di compensazione pianificata.

Jean-Paul Kress, CEO, Presidente y Director de Vor Biopharma, recibi贸 una importante concesi贸n de opciones sobre acciones el 26 de junio de 2025. La transacci贸n con valores derivados involucr贸 83.296.638 opciones sobre acciones con los siguientes t茅rminos clave:

  • Precio de ejercicio establecido en $0.89 por acci贸n
  • Las opciones expiran el 25 de junio de 2035
  • Calendario de adquisici贸n: 25% se adquiere el 26 de junio de 2026, y el 75% restante se adquiere en cuotas mensuales iguales durante 3 a帽os
  • La adquisici贸n depende de la continuidad en el servicio dentro de la empresa

Esta significativa concesi贸n de acciones alinea los intereses del CEO con los de los accionistas y sugiere un compromiso a largo plazo con la empresa. El bajo precio de ejercicio en comparaci贸n con los precios habituales de acciones biotecnol贸gicas puede indicar desaf铆os recientes en el mercado o una planificaci贸n estrat茅gica de compensaci贸n.

鞛�-韽� 韥爤鞀�, Vor Biopharma鞚� CEO, 須岇灔 氚� 鞚挫偓電� 2025雲� 6鞗� 26鞚检棎 靸侂嫻頃� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 韺岇儩歃濌秾 瓯半灅電� 83,296,638欤�鞚� 欤检嫕毵れ垬靹犿儩甓岇潉 韽暔頃橂┌, 欤检殧 臁瓣贝鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 頄夓偓臧�瓴�: 欤茧嫻 $0.89
  • 鞓奠厴 毵岆鞚�: 2035雲� 6鞗� 25鞚�
  • 氩犾姢韺� 鞚检爼: 2026雲� 6鞗� 26鞚检棎 25% 氩犾姢韺�, 雮橂ǜ歆� 75%電� 3雲� 霃欖晥 毵れ洈 霃欖澕 牍勳湪搿� 氩犾姢韺�
  • 氩犾姢韺呾潃 須岇偓 攴茧 歆�靻� 臁瓣贝攵�

鞚措煬頃� 雽�攴滊 欤检嫕 攵�鞐姅 CEO鞚� 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偆瓿� 須岇偓鞐� 雽�頃� 鞛リ赴鞝侅澑 項岇嫚鞚� 雮橅儉雰呺媹雼�. 鞚茧皹鞝侅澑 氚旍澊鞓ろ厤 欤缄皜鞐� 牍勴暣 雮潃 頄夓偓臧�瓴╈潃 斓滉芳 鞁滌灔鞚� 鞏措牑鞗�鞚措倶 鞝勲灥鞝� 氤挫儊 瓿勴殟鞚� 氚橃榿頃� 靾� 鞛堨姷雼堧嫟.

Jean-Paul Kress, PDG, Pr茅sident et Directeur de Vor Biopharma, a re莽u une attribution importante d鈥檕ptions d鈥檃chat d鈥檃ctions le 26 juin 2025. La transaction portant sur des titres d茅riv茅s comprenait 83 296 638 options d鈥檃chat avec les conditions cl茅s suivantes :

  • Prix d鈥檈xercice fix茅 脿 0,89 $ par action
  • Les options expirent le 25 juin 2035
  • Calendrier d鈥檃cquisition : 25 % acquis le 26 juin 2026, les 75 % restants acquis par tranches mensuelles 茅gales sur 3 ans
  • L鈥檃cquisition est conditionn茅e 脿 la poursuite du service au sein de l鈥檈ntreprise

Cette importante attribution d鈥檃ctions aligne les int茅r锚ts du PDG sur ceux des actionnaires et sugg猫re un engagement 脿 long terme envers l鈥檈ntreprise. Le faible prix d鈥檈xercice, compar茅 aux cours habituels des actions biotechnologiques, pourrait refl茅ter des difficult茅s r茅centes du march茅 ou une planification strat茅gique de la r茅mun茅ration.

Jean-Paul Kress, CEO, Vorsitzender und Direktor von Vor Biopharma, erhielt am 26. Juni 2025 eine bedeutende Gew盲hrung von Aktienoptionen. Die Transaktion mit derivativen Wertpapieren umfasste 83.296.638 Aktienoptionen mit folgenden wesentlichen Bedingungen:

  • Aus眉bungspreis festgelegt auf 0,89 $ pro Aktie
  • Optionen verfallen am 25. Juni 2035
  • Vesting-Plan: 25 % werden am 26. Juni 2026 f盲llig, die restlichen 75 % werden gleichm盲脽ig monatlich 眉ber 3 Jahre verteilt freigegeben
  • Vesting ist an die fortgesetzte T盲tigkeit im Unternehmen gebunden

Diese bedeutende Aktienzuteilung bringt die Interessen des CEO mit denen der Aktion盲re in Einklang und deutet auf ein langfristiges Engagement f眉r das Unternehmen hin. Der niedrige Aus眉bungspreis im Vergleich zu 眉blichen Biotech-Aktienkursen k枚nnte auf j眉ngste Marktprobleme oder eine strategische Verg眉tungsplanung hinweisen.

Positive
  • None.
Negative
  • None.

Jean-Paul Kress, CEO, Presidente e Direttore di Vor Biopharma, ha ricevuto un importante premio in opzioni azionarie il 26 giugno 2025. La transazione riguardante strumenti derivati ha coinvolto 83.296.638 opzioni azionarie con le seguenti condizioni principali:

  • Prezzo di esercizio fissato a 0,89 $ per azione
  • Le opzioni scadono il 25 giugno 2035
  • Piano di maturazione: 25% matura il 26 giugno 2026, mentre il restante 75% matura in rate mensili uguali distribuite su 3 anni
  • La maturazione 猫 subordinata alla continuazione del servizio in azienda

Questa consistente assegnazione di azioni allinea gli interessi del CEO con quelli degli azionisti e indica un impegno a lungo termine verso l鈥檃zienda. Il prezzo di esercizio basso, rispetto ai tipici valori delle azioni biotech, potrebbe riflettere recenti difficolt脿 di mercato o una strategia di compensazione pianificata.

Jean-Paul Kress, CEO, Presidente y Director de Vor Biopharma, recibi贸 una importante concesi贸n de opciones sobre acciones el 26 de junio de 2025. La transacci贸n con valores derivados involucr贸 83.296.638 opciones sobre acciones con los siguientes t茅rminos clave:

  • Precio de ejercicio establecido en $0.89 por acci贸n
  • Las opciones expiran el 25 de junio de 2035
  • Calendario de adquisici贸n: 25% se adquiere el 26 de junio de 2026, y el 75% restante se adquiere en cuotas mensuales iguales durante 3 a帽os
  • La adquisici贸n depende de la continuidad en el servicio dentro de la empresa

Esta significativa concesi贸n de acciones alinea los intereses del CEO con los de los accionistas y sugiere un compromiso a largo plazo con la empresa. El bajo precio de ejercicio en comparaci贸n con los precios habituales de acciones biotecnol贸gicas puede indicar desaf铆os recientes en el mercado o una planificaci贸n estrat茅gica de compensaci贸n.

鞛�-韽� 韥爤鞀�, Vor Biopharma鞚� CEO, 須岇灔 氚� 鞚挫偓電� 2025雲� 6鞗� 26鞚检棎 靸侂嫻頃� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 韺岇儩歃濌秾 瓯半灅電� 83,296,638欤�鞚� 欤检嫕毵れ垬靹犿儩甓岇潉 韽暔頃橂┌, 欤检殧 臁瓣贝鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 頄夓偓臧�瓴�: 欤茧嫻 $0.89
  • 鞓奠厴 毵岆鞚�: 2035雲� 6鞗� 25鞚�
  • 氩犾姢韺� 鞚检爼: 2026雲� 6鞗� 26鞚检棎 25% 氩犾姢韺�, 雮橂ǜ歆� 75%電� 3雲� 霃欖晥 毵れ洈 霃欖澕 牍勳湪搿� 氩犾姢韺�
  • 氩犾姢韺呾潃 須岇偓 攴茧 歆�靻� 臁瓣贝攵�

鞚措煬頃� 雽�攴滊 欤检嫕 攵�鞐姅 CEO鞚� 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偆瓿� 須岇偓鞐� 雽�頃� 鞛リ赴鞝侅澑 項岇嫚鞚� 雮橅儉雰呺媹雼�. 鞚茧皹鞝侅澑 氚旍澊鞓ろ厤 欤缄皜鞐� 牍勴暣 雮潃 頄夓偓臧�瓴╈潃 斓滉芳 鞁滌灔鞚� 鞏措牑鞗�鞚措倶 鞝勲灥鞝� 氤挫儊 瓿勴殟鞚� 氚橃榿頃� 靾� 鞛堨姷雼堧嫟.

Jean-Paul Kress, PDG, Pr茅sident et Directeur de Vor Biopharma, a re莽u une attribution importante d鈥檕ptions d鈥檃chat d鈥檃ctions le 26 juin 2025. La transaction portant sur des titres d茅riv茅s comprenait 83 296 638 options d鈥檃chat avec les conditions cl茅s suivantes :

  • Prix d鈥檈xercice fix茅 脿 0,89 $ par action
  • Les options expirent le 25 juin 2035
  • Calendrier d鈥檃cquisition : 25 % acquis le 26 juin 2026, les 75 % restants acquis par tranches mensuelles 茅gales sur 3 ans
  • L鈥檃cquisition est conditionn茅e 脿 la poursuite du service au sein de l鈥檈ntreprise

Cette importante attribution d鈥檃ctions aligne les int茅r锚ts du PDG sur ceux des actionnaires et sugg猫re un engagement 脿 long terme envers l鈥檈ntreprise. Le faible prix d鈥檈xercice, compar茅 aux cours habituels des actions biotechnologiques, pourrait refl茅ter des difficult茅s r茅centes du march茅 ou une planification strat茅gique de la r茅mun茅ration.

Jean-Paul Kress, CEO, Vorsitzender und Direktor von Vor Biopharma, erhielt am 26. Juni 2025 eine bedeutende Gew盲hrung von Aktienoptionen. Die Transaktion mit derivativen Wertpapieren umfasste 83.296.638 Aktienoptionen mit folgenden wesentlichen Bedingungen:

  • Aus眉bungspreis festgelegt auf 0,89 $ pro Aktie
  • Optionen verfallen am 25. Juni 2035
  • Vesting-Plan: 25 % werden am 26. Juni 2026 f盲llig, die restlichen 75 % werden gleichm盲脽ig monatlich 眉ber 3 Jahre verteilt freigegeben
  • Vesting ist an die fortgesetzte T盲tigkeit im Unternehmen gebunden

Diese bedeutende Aktienzuteilung bringt die Interessen des CEO mit denen der Aktion盲re in Einklang und deutet auf ein langfristiges Engagement f眉r das Unternehmen hin. Der niedrige Aus眉bungspreis im Vergleich zu 眉blichen Biotech-Aktienkursen k枚nnte auf j眉ngste Marktprobleme oder eine strategische Verg眉tungsplanung hinweisen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kress Jean-Paul
(Last) (First) (Middle)
C/O VOR BIOPHARMA INC.
100 CAMBRIDGEPARK DRIVE, SUITE 101
(Street)
CAMBRIDGE MA 02140
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and Chairman
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $0.89 06/26/2025 A 83,296,638 (1) 06/25/2035 Common Stock 83,296,638 $0 83,296,638 D
Explanation of Responses:
1. 1/4th of the shares underlying the option vest on June 26, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
/s/ Sherell Bacchas, Attorney-in-Fact 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many stock options did VOR's CEO Jean-Paul Kress receive on June 26, 2025?

VOR's CEO and Chairman Jean-Paul Kress received 83,296,638 employee stock options with an exercise price of $0.89 per share on June 26, 2025.

What is the vesting schedule for VOR CEO's new stock options granted in June 2025?

The stock options vest over 4 years, with 25% vesting on June 26, 2026 (one year after grant), and the remaining 75% vesting in equal monthly installments over the following 3 years, subject to continued service.

When do VOR CEO Jean-Paul Kress's June 2025 stock options expire?

The stock options granted to Jean-Paul Kress on June 26, 2025, expire on June 25, 2035, giving him a 10-year period to exercise the options.

What is the exercise price of VOR's stock options granted to CEO in June 2025?

The exercise price of the stock options granted to VOR's CEO is $0.89 per share.

What positions does Jean-Paul Kress hold at VOR Biopharma as of June 2025?

According to the Form 4 filing, Jean-Paul Kress serves as both CEO and Chairman of the Board at VOR Biopharma Inc.
Stock VOR logo
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

#6537 Ranked by Market Cap
N/A Ranked by Dividends
#70 Top Gainer

VOR Latest News

Jul 1, 2025
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 26, 2025
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
Jun 25, 2025
Vor Bio Announces $175 Million Private Placement
Jun 25, 2025
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
May 8, 2025
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

VOR Latest SEC Filings

Jul 1, 2025
[144] Vor Biopharma Inc. SEC Filing
Jun 30, 2025
[144] Vor Biopharma Inc. SEC Filing
Jun 27, 2025
[SCHEDULE 13D/A] Vor Biopharma Inc. SEC Filing
Jun 27, 2025
[Form 3] Vor Biopharma Inc. Initial Statement of Beneficial Ownership

VOR Stock Data

39.75M
85.11M
32.03%
49.54%
1.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE